Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Goodwill and intangible assets

9 Months Ended

Apr. 30, 2018

Note 5 – Goodwill and intangible assets

At April 30, 2018 and July 31, 2017, the Company’s carrying amount of goodwill, related to the Clinical Labs segment, is $7,452.

The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows:

	Gross		Accumulated Amortization			Net
July 31, 2017	$	27,436	$	(24,541	)	$	2,895
Amortization expense		—		(742	)		(742	)
Foreign currency translation		2		(6	)		(4	)
April 30, 2018	$	27,438	$	(25,289	)	$	2,149

Intangible assets, all finite lived, consist of the following:

	April 30, 2018							July 31, 2017
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Patents	$	11,027	$	(10,971	)	$	56	$	11,027	$	(10,951	)	$	76
Customer relationships		11,892		(9,799	)		2,093		11,881		(9,083	)		2,798
Website and acquired content		1,010		(1,010	)		—		1,011		(1,011	)		—
Licensed technology and other		492		(492	)		—		484		(463	)		21
Trademarks		3,017		(3,017	)		—		3,033		(3,033	)		—
Total	$	27,438	$	(25,289	)	$	2,149	$	27,436	$	(24,541	)	$	2,895

At April 30, 2018, information with respect to intangibles assets acquired is as follows:

	Useful life assigned	Weighted average remaining useful life
Customer relationships	8 -15 years	2.5 years
Other intangibles	10 years	1.5 years

At April 30, 2018, the weighted average remaining useful life of intangible assets is approximately two years.